Myeloproliferative Neoplasm, BCR-ABL1 Negative

Myeloproliferative Neoplasm, BCR-ABL1 Negative — Trials · CancerIndex

Clinical trials

Registered studies

333 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 94
Recruiting: 50
Ph III recruiting: 7
Growth YoY: —
Industry share: 41%
Top sponsor: City of Hope Medical Center
Termination share: 35.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (56)

clinicaltrialsPublishedShowing 101–150 of 333 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03912064	A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT	active not recruiting	Phase 1	25	Dana-Farber Cancer InstituteOTHER	1	Jan 5, 2026	clinicaltrials
NCT00255346	Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)	completed	Phase 2	68	M.D. Anderson Cancer CenterOTHER	1	Dec 30, 2025	clinicaltrials